Active, not recruitingPhase 2NCT05563844

Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

Studying Epstein-Barr virus-positive diffuse large B-cell lymphoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Chengdu Zenitar Biomedical Technology Co., Ltd
Principal Investigator
Ting Niu, Doctor
West China Hospital
Intervention
PM 8.4 mg/m^2(drug)
Enrollment
74 enrolled
Eligibility
18 years · All sexes
Timeline
20222027

Study locations (2)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05563844 on ClinicalTrials.gov

Other trials for Epstein-Barr virus-positive diffuse large B-cell lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Epstein-Barr virus-positive diffuse large B-cell lymphoma

← Back to all trials